Levodopa/carbidopa/entacapone - Orion

Drug Profile

Levodopa/carbidopa/entacapone - Orion

Alternative Names: ODM-101

Latest Information Update: 31 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Class Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 21 Mar 2013 Efficacy & adverse events data from a phase II trial in Parkinson's disease presented at the 65th Annual Meeting of the American Academy of Neurology (AAN-2013)
  • 24 Oct 2012 Levodopa/carbidopa/entacapone - Orion is available for licensing as of 30 Sep 2012. http://www.orion.fi/
  • 23 Oct 2012 Efficacy data from a phase II trial in Parkinson's disease released by Orion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top